Thyrocare Technologies Share Price Today

Thyrocare sells Nucleur Healthcare stake to Trovera for ₹141.4 crore

Thyrocare sells 100% stake in Nucleur Healthcare to Trovera for ₹141.4 crore. Consideration includes ₹59.5 crore in Trovera CCPS and ~₹81.9 crore in cash. NHL contributed 5.38% of consolidated turnover and 14.27% of net worth in FY26. Board approves purchase of Gurugram and Hyderabad properties from NHL for ₹20.59 crore. Transaction requires shareholder approval under Regulation 37A of SEBI Listing Regulations.

API Holdings updates pledge release disclosure for Thyrocare shares

API Holdings updated disclosure on release of pledge for 7,94,69,696 Thyrocare shares. Pledge was fully released on August 17, 2026, prior to amalgamation. Update follows September 3 effective date of Docon-API merger. Catalyst Trusteeship Limited acted as Debenture Trustee for the pledge. Filing complies with SEBI SAST Regulations 31(2) and 31(3).

Thyrocare promoter Docon releases pledge on 7.95 crore shares after debt repayment

Thyrocare Technologies promoter Docon Technologies has fully released the pledge on 7.95 crore shares after API Holdings repaid ₹10,500 million in NCDs. Catalyst Trusteeship issued the release certificate on August 19, 2026, discharging all transaction documents. This completes the de-encumbrance process initiated with a partial release earlier in August, leaving Docon with an unpledged stake of 51.02% in the diagnostics firm.

Thyrocare promoter Docon sells 9.9% stake in market trades

Thyrocare Technologies promoter Docon Technologies sold 1.57 crore shares (9.9% stake) in market trades on August 13, 2026. Promoter holding drops to 51.02% from 60.92%. Disclosure filed under SEBI Takeover Regulation 29(2).

Thyrocare Q2 Results: Revenue guidance expected to be raised post Q2

Thyrocare Technologies is expected to raise its revenue guidance after Q2 results. The promoter pledge on shares has been lifted. No stake sale is planned by the promoters.

Thyrocare Q1FY27 PAT rises 34% to ₹51.33 crore on volume surge

Thyrocare Technologies delivered strong Q1FY27 results with PAT rising 34% to ₹51.33 crore and revenue growing 24% to ₹240.02 crore. Key developments include the launch of specialty diagnostics, expansion of the franchisee network to 11,700, and plans to divest the radiology segment to improve return on capital employed.